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Abstract
The Z protein is the matrix protein of arenaviruses and has been identified as the main driving force
for budding. Both LCMV and Lassa virus Z proteins bud from cells in the absence of other viral
proteins as enveloped virus-like particles. Z accumulates near the inner surface of the plasma
membrane where budding takes place. Furthermore, biochemical data have shown that Z is
strongly membrane associated. The primary sequence of Z lacks a typical transmembrane domain
and until now it is not understood by which mechanism Z is able to interact with cellular
membranes. In this report, we analyzed the role of N-terminal myristoylation for the membrane
binding of Lassa virus Z. We show that disruption of the N-terminal myristoylation signal by
substituting the N-terminal glycine with alanine (Z-G2A mutant) resulted in a significant reduction
of Z protein association with cellular membranes. Furthermore, removal of the myristoylation site
resulted in a relocalization of Z from a punctuate distribution to a more diffuse cellular distribution
pattern. Finally, treatment of Lassa virus-infected cells with various myristoylation inhibitors
drastically reduced efficient Lassa virus replication. Our data indicate that myristoylation of Z is
critical for its binding ability to lipid membranes and thus, for effective virus budding.
Background
Lassa virus (LASV) belongs of the family of Arenaviridae.
Based on phylogenetical, serological, and geographical
findings, this family can be subdivided into two groups:
The Old World group includes the prototype of this fam-
ily, the lymphocytic choriomeningitis virus (LCMV) as
well as Lassa virus. The New World group (also known as
Tacaribe complex) includes other important human path-
ogens like Machupo virus, Junin virus, Guanarito virus
and Sabia virus which are responsible for hemorrhagic
fever outbreaks in South American countries. LASV is the
causative agent of human Lassa fever, a viral hemorrhagic
fever disease that is endemic in certain countries of West
Africa. As a potential bioterrorism threat and due to the
lack of an effective, safe therapy, Lassa virus has emerged
as a worldwide concern.
Lassa virus is an enveloped virus that contains a bi-seg-
mented single-stranded RNA genome. Each RNA segment
encodes two viral genes in an ambisense coding strategy
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separated by an intergenic region. The small RNA (S-RNA)
segment encodes the nucleoprotein NP and the glycopro-
tein precursor preGP-C which undergoes co- and post-
translational cleavage events in order to obtain its mature
form [1-5]. The large RNA (L-RNA) segment encodes the
RNA-dependent RNA polymerase L and the Z protein
[6,7].
Although the information available so far indicates multi-
ple functions of Z, the role of Z during different stages in
the arenavirus life cycle is still poorly understood. Several
cellular factors have been described to interact with Z, e.g.
the promyelocytic leukemia protein (PML), the nuclear
fraction of the ribosomal protein P0, and the eukaryotic
translation initiation factor 4E. However, the biological
role of these interactions still remains largely unknown
[8-10]. Z also exhibits a dose-dependent inhibitory effect
on RNA synthesis, and cells expressing the Z protein are
resistant to LCMV and Lassa virus infection [11,12]. In
addition to its multifunctional regulatory role in the are-
navirus life cycle, Z is also a structural component of the
virus particle [13]. It has been shown that Z is the arenavi-
rus counterpart to matrix proteins found in other nega-
tive-stranded RNA viruses [14,15]. In Lassa virus-infected
cells, Z is mainly localized at the inner surface of the
plasma membrane. Z protein of Lassa virus interacts with
lipid membranes and can form enveloped particles that
are similar in diameter and morphology to those particles
released from Lassa virus-infected cells [15,16]. Further-
more, using biochemical methods we demonstrated that
Z is highly membrane-associated. Membrane-detachment
studies of Z revealed that treatment with chaotropic
agents which characteristically remove most peripheral
membrane proteins, had no effect on the association of Z
with membranes [15]. The nature of this tight membrane
interaction is still unknown since Z is lacking a character-
istic hydrophobic transmembrane domain. Alignment of
the amino acid sequences of several Z proteins revealed
the presence of a putative myristoylation site at the glycine
position 2 in context of a potential myristoylation signal
motif that is highly conserved among New and Old World
arenavirus Z proteins (Fig. 1). It has been shown recently
that both LCMV and LASV Z are targets for attachment of
myristic acid [17]. Mutation of the glycine at position 2,
thereby disrupting the myristoylation signal prevented the
incorporation of myristic acid. As a consequence Z-medi-
ated budding activity was impaired [17]. Further evidence
of the importance of myristoylation in arenavirus bud-
ding was provided by studies of Cordo et al. [18] showing
that treatment with myristic acid analogs inhibited the
replication of the New World arenaviruses Junin and
Tacaribe. Thus, myristoylation of arenavirus proteins
seems to be a crucial modification necessary for efficient
virus replication.
N-myristoylation is a co-translational event in which myr-
istate (a 14-carbon fatty acid) is covalently attached to an
N-terminal glycine. This reaction is catalyzed by the
enzyme N-myristoyl transferase (NMT) using myristoyl-
CoA as a substrate upon removal of the initiator methio-
nine by a methionine aminopeptidase [19]. N-myristoyla-
tion is a common lipid modification of proteins in
eukaryotes and essential for the function of proteins
involved in many cellular pathways of signal transduc-
tion, apoptosis and oncogenesis [20-24]. In addition, an
increasing number of viral and bacterial proteins have
been also reported to be myristoylated [25-27]. Modifica-
tion of viral proteins by myristic acid plays an important
role at different stages of the virus life cycle [28-36]. N-
myristoylation can influence protein-protein interaction
and the conformational stability of proteins as well as
mediating membrane targeting and binding [22].
In this study, we investigated the contribution of N-myris-
toylation to the membrane binding ability of the Lassa
virus Z protein. We demonstrate that myristoylation is
required for efficient binding of Z to cellular membranes.
Using a flotation assay we show that the mutant Z-G2A in
which the amino-terminal glycine residue was changed to
alanine exhibited a strongly reduced membrane binding
affinity compared to wild-type Z protein. As a conse-
quence, the budding activity of this mutant was impaired.
Interestingly, the removal of myristic acid also affected the
cellular localization of Z indicating that myristoylation is
important for Z targeting to specific cellular regions.
Finally, treatment of LASV-infected cells with myristoyla-
tion inhibitors resulted in significant decrease of LASV
particle release. Our data indicate that myristoylation of Z
is critical for its binding ability to lipid membranes and
thus, for effective virus budding.
Results
Myristoylation of Z is not required for stability
In addition to its role in membrane anchoring, myris-
toylation was also reported to contribute to the stability of
proteins [37]. To compare the stability of wild-type Z and
a non-myristoylated mutant, we constructed a mutant,
designated Z-G2A, in which the glycine at position 2 was
exchanged to alanine (Fig. 1). This mutation disrupts the
myristic acid attachment site and does not allow incorpo-
ration of myristic acid [17]. To address whether the
removal of myristic acid affects the stability of Z and there-
fore undergoes faster degradation, we performed pulse-
chase experiments of Z-G2A and Z-WT for up to 5 h. As
shown in Fig. 2, both Z-WT and Z-G2A were expressed to
similar levels and no significant change in the stability
was observed. Therefore, we conclude that the removal of
the myristic acid has no effect on the overall stability of Z
and, thus, the myristoyl group in Z is not involved in
intramolecular stabilization. Interestingly, a second band
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was observed in the Z-G2A construct which appeared with
a molecular mass slightly higher than the main band.
However, the identity of this band remains to be deter-
mined.
Myristoylation mediates efficient membrane association 
of Z
We have previously shown that solitary expressed Z has an
intrinsic membrane-binding capacity [15]. Up to now the
mechanism by which Z interacts with cellular membranes
is still unknown. However, myristic acid attachment has
been shown to play an important role in plasma mem-
brane targeting and binding [36,38,39]. Thus, we wanted
to investigate the role of myristoylation in the ability of Z
to bind to lipid membranes. We performed membrane
flotation analysis of the Z-G2A mutant in comparison to
wild-type Z protein as described previously [15]. Huh7
cells expressing either Z-WT or Z-G2A were disrupted and
the post-nuclear supernatants were subjected to flotation.
Cellular membranes and membrane-associated proteins
float to the OptiPrep-TNE interface during ultracentrifu-
gation whereas soluble proteins remain at the bottom.
Fractions were collected from the top of the gradient and
analyzed by SDS-PAGE with subsequent Western Blotting.
As described before, wild-type Z efficiently floated into
the interface between 30% OptiPrep and TNE (fraction 1)
showing that the Z protein is associated with cellular
membranes (Fig. 3A). In contrast, the exchange of glycine
to alanine at position 2 resulted in a clear shift of a major
fraction of Z-G2A from a membrane to a cytosolic locali-
zation. Thus, we conclude that myristoylation contributes
to efficient membrane binding of Z.
Mutation of the glycine at position 2 is critical for LASV Z-
driven VLP formation
For a number of viruses it has been shown that stable asso-
ciation of viral proteins with cellular membranes is
required for virus assembly and production of virus parti-
cles. Lassa virus Z protein is sufficient to drive the release
of Z containing VLPs that are surrounded by a lipid enve-
lope [15]. Therefore we analyzed whether membrane
binding through myristoylation is a prerequisite for Z-
induced budding. To test this, supernatants of Huh7 cells
expressing Z-WT or Z-G2A were subjected to ultracentrif-
ugation (UC) through a 20% sucrose cushion. The UC-
pelleted VLPs and cell lysates were analyzed by SDS-PAGE
followed by immunoblotting using Z-specific antisera. As
shown in Fig. 3B, the amount of Z released into the super-
Schematic representation of LASV Z proteinFigure 1
Schematic representation of LASV Z protein. Amino acids associated with particular structures and functions are 
shown in single letters. The myristoylated glycine residue at amino acid position 2 is shown in bold letters. Cysteine- and histi-
dine residues forming the RING finger domain (C, cysteine; H, histidine) as well as the late domain motifs PPPY and PTAP (P, 
proline; Y, tyrosine; T, threonine; A, alanine) are indicated. Alignment of the N-termini of Old and New World arenavirus Z 
protein sequences are shown. Conserved glycine residues at position 2 are highlighted in bold letters. To generate the non-
myristoylated mutant Z-G2A of LASV Z protein, site-directed mutagenesis was used to change the N-terminal glycine codon 
to an alanine codon.
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natant of Z-G2A expressing cells was significantly
decreased compared to wild-type Z although proteins
were expressed at comparable levels. Thus, consistent with
the report of Perez et al. [17] mutation of the glycine at
position 2 results in reduced Z-mediated formation of
VLPs. Our data indicate that membrane-binding of Z is an
important prerequisite to fulfill its budding function.
Z-G2A mutant exhibits altered cellular localization
Next, we wanted to determine whether the loss of myris-
toylation affects the subcellular localization of Z. There-
fore, we performed indirect immunofluorescence
microscopic analysis in order to determine the cellular
distribution of Z-G2A and Z-WT in the presence of the
myristoylation inhibitor DL-2-hydroxymyristic acid (2
OHM), an inhibitor of N-myristoyltransferase. Consistent
with our previous data, wild-type Z was distributed in a
punctuate fashion throughout the cytoplasm including
localization at the plasma membrane as well as the peri-
nuclear region (Fig. 4A). In contrast, cells expressing the
non-myristoylated Z-G2A mutant showed a much more
diffused distribution pattern and Z was mainly found to
be accumulated in the perinuclear region. (Fig. 4B). Simi-
lar results were obtained with Vero cells expressing Z-WT
in the presence of the myristoylation inhibitor 2 OHM
(Fig. 4C). Our data suggest that punctuate structures tar-
geted by myristoylated Z represent cellular regions impor-
tant for assembly and budding.
Inhibition of LASV replication by blocking myristoylation
Inhibitors of myristoylation have been reported to inhibit
the replication of a wide range of viruses including the
Old and New World arenaviruses LCMV and Junin,
respectively [17,18,29,31,40-42]. However the impact of
blocking myristoylation on LASV replication has not been
addressed yet. Therefore we assessed the inhibitory effect
of DL-2-hydroxymyristic acid (2 OHM), 13-oxamyristic
acid (13 OM) and 4-oxatetradecanoic acid on the multi-
plication of LASV. Vero cells were infected with LASV and
1 hour post-adsorption, cells were either treated with myr-
istoylation inhibitors at indicated concentrations or left
untreated. After 48 hours, supernatants were harvested
Stability of LASV Z in the presence or absence of myristic acidFigure 2
Stability of LASV Z in the presence or absence of myristic acid. Huh7 cells were transfected with the pCAGGS vector 
encoding Z-WT and Z-G2A mutant, respectively. Cells were metabolically labelled with 35S-methionine/-cysteine for 30 min 
and chased for various time intervals as indicated. Samples were precipitated using anti-Z-antiserum, subjected to SDS-PAGE 
on 15% polyacrylamide gels and analyzed using a FUJI BAS 1000 BioImaging analyser system (raytest).
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A. Membrane association of LASV Z wild-type and Z-G2A mutantFigure 3
A. Membrane association of LASV Z wild-type and Z-G2A mutant. Huh7 cells were transfected with wild-type Z and 
Z-G2A mutant, respectively and 24 h post-transfection, flotation analysis was performed as described in Materials and Methods. 
Aliquots of the fractionated gradient were subjected to SDS-PAGE followed by immunoblotting using specific antisera against 
Z. Visualization was carried out with Odyssey™ Infrared Imaging System using a goat anti-rabbit secondary antibody labelled 
with Alexa680. B. VLP formation of Z-WT and Z-G2A. Cellular supernatants of Z-WT- or Z-G2A-transfected Huh7 cells 
were collected after 48 h, freed from cellular debris and then pelleted through a 20% sucrose cushion by ultracentrifugation 
(UC). UC-pellet containing VLPs and cell lysates as a control were dissolved in SDS-PAGE sample buffer and analyzed by SDS-
PAGE and immunoblotting.
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and virus yields were measured by defining the 50% tissue
culture infectious dose (TCID50). In the presence of myr-
istoylation inhibitors a significant reduction in virus titers
was observed compared to untreated LASV-infected cells
indicating that myristoylation plays an important role in
the life cycle of LASV (Fig. 5A). DL-2-hydroxymyristic acid
and 13-oxamyristic acid exhibited similar effects and
reduced virus production up to 3 log10 at a final concen-
tration of 100 µM. 4-oxatetradecanoic acid was found to
be less active but still able to reduce virus release up to 2
log10 compared to untreated infected cells. In order to
investigate the effect of blocking myristoylation on virus
particle release, cell lysates and supernatants of infected
cells were analyzed by SDS-PAGE and immunoblotting.
Fig. 5B shows exemplarily the inhibitory potential of 13
OM. The amount of viral proteins in the supernatant of 13
OM-treated cells was highly decreased compared to
untreated LASV-infected cells although the intracellular
expression levels were similar. Detection of beta-actin was
used to demonstrate that treatment of cells with myristic
Subcellular localization of Z-G2A and Z-WT in the presence or absence of 2 OHMFigure 4
Subcellular localization of Z-G2A and Z-WT in the presence or absence of 2 OHM. Vero cells expressing A. Z-WT 
B. Z-G2A C. Z-WT in the presence of 2 OHM (100 µM final concentration) D. Mock transfection. Cells were fixed with ace-
tone/methanol and incubated with an anti-Z polyclonal antiserum and a FITC-conjugated secondary antibody.
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acid inhibitors does not effect cellular protein expression.
Similar results were observed for DL-2-hydroxymyristic
acid and 4-oxatetradecanoic acid (data not shown). Taken
together, our data clearly demonstrate that myristoylation
is important for efficient LASV assembly and virus particle
release.
Discussion
In the present report, we analyzed the role of N-myris-
toylation for the membrane binding properties of LASV Z
and its function during virus release. We created a mutant
(Z-G2A) that has been shown to fail the incorporation of
myristic acid [17] to demonstrate that in the absence of
the myristoyl moiety, Z was not efficiently associated with
membranes. These results are in agreement with reports
for other proteins showing that N-myristoylation is
important for membrane binding [36,38,39]. Although
the disruption of the myristoylation motif resulted in a
clear shift of Z from the membrane to the cytosolic frac-
tion, a minor fraction of Z was still found to be associated
with membranes indicating that additional factors might
be involved in membrane binding. It is known that many
myristoylated proteins like the transforming protein
pp60v-src of Rous sarcoma virus or the HIV gag and nef
proteins need a cluster of basic amino acids close to the
myristoylation site for efficient membrane binding [43-
45]. This "myristate plus basic" motif synergizes hydro-
phobic and electrostatic forces resulting in strong mem-
brane binding. Interestingly, LASV Z contains basic amino
acids downstream of the myristoylated glycine residue
(Myr-GNKQAKAPESKDSPR...) which show some similar-
ity to those present in the N-terminus of the transforming
protein pp60v-src (Myr-GSSKSKPKDPSQR...) of Rous sar-
coma virus. The role of basic amino acids and/or addi-
tional hydrophobic sequences within Z for membrane
binding is currently under investigation. However, the
glycine to alanine exchange was sufficient enough to sig-
nificantly reduce the release of Z-mediated VLPs. These
results are in line with data published by Perez et al. [17]
showing that mutation of the glycine at position 2 is crit-
ical for VLP formation. Our data suggest that assembly
and budding of Lassa virus requires membrane binding of
Z to which the myristoyl moiety greatly contributes.
N-terminal myristoylation of LASV Z is not only impor-
tant for efficient membrane binding but also participate
in targeting Z to specific cellular regions. Unlike wild-type
Z, the non-myristoylated mutant Z-G2A shows a diffuse
distribution pattern throughout the cytoplasm and accu-
mulates in the perinuclear region. The change from a
punctuate staining for wild-type to a diffuse cellular distri-
bution for a non-myristoylated mutant has also been
described for HIV-1 gag [46]. Our results suggest myris-
toylation-mediated targeting of Z to specific cellular
regions that are important for efficient LASV budding.
The data presented in this work as well as results described
by Perez et al. [17] demonstrate that myristoylation of Z
plays a key role in arenavirus budding. Treatment of LASV
with myristoylation inhibitors resulted in drastic reduc-
tion of infectious virus particle production. Although we
have shown that myristoylation is crucial for the correct
function of Z, it cannot be excluded that other LASV pro-
teins might require myristoylation for their function dur-
ing virus replication. For the glycoprotein GP of the New
world arenavirus Junin virus it was recently shown that its
signal peptide is myristoylated and mutation of this myr-
istoylation motif resulted in reduced membrane fusion
activity of GP [47]. Similar results were observed for LASV
GP (T. Strecker, unpublished results). Thus, myristoyla-
tion inhibitors might target multiple arenaviral proteins
and therefore may have the potential to serve as an antivi-
ral drug against Lassa virus and other arenaviruses causing
hemorrhagic fever in humans.
Conclusion
Our findings indicate that N-myristoylation of LASV Z
plays an important role in both targeting to and associa-
tion with specific cellular membranes that are important
for assembly and budding.
Materials and methods
Cell cultures and viruses
Human hepatoma (Huh7) cells and green monkey kidney
(VeroE6) cells were cultured in Dulbecco's modified
Eagle's medium (DMEM, Gibco) supplemented with 10%
fetal calf serum, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin. Lassa virus, strain Josiah, was grown on
VeroE6 and Huh7 cells, respectively. Infection with Lassa
virus was carried out at a MOI of 0.1. All experiments per-
formed with Lassa virus were done under biosafety level 4
biocontainment conditions at the Institute of Virology in
Marburg, Germany.
Molecular cloning and vectorial expression
The open reading frame of Lassa virus Z protein (Lassa
virus strain Josiah) was expressed using the pCAGGS vec-
tor as described previously [15]. The Z myristoylation
mutant, designated Z-G2A, in which the glycine at posi-
tion 2 was exchanged to alanine was generated by stand-
ard PCR techniques. A list of the respective
oligonucleotides will be made available on request. The
accuracy of all constructs was confirmed by DNA sequenc-
ing. Huh7 and VeroE6 cells were transfected with wild
type and mutated recombinant DNA using Lipofectamine
2000 (Gibco/Invitrogen).
Antibodies and reagents
Antisera against GP-C, NP and Z protein were raised by
immunization of rabbits as described previously [5,48].
Anti-beta actin antibody was purchased from Abcam
Virology Journal 2006, 3:93 http://www.virologyj.com/content/3/1/93
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(UK). Secondary antibodies conjugated with horse radish
peroxidase were purchased from DAKO (USA). Secondary
antibodies labelled with Alexa680 (700 nm) were from
Molecular Probes™ Invitrogen (Germany) and were used
for visualization of proteins using Odyssey™ Infrared
Imaging System (Li-Cor Biosciences). Myristic acid inhib-
itors DL-2-hydroxymyristic acid (2 OHM), 13-oxamyristic
acid (13 OM) and 4-oxatetradecanoic acid (4 OXA) were
purchased from Sigma-Aldrich (Germany). Stock solu-
tions were prepared in ethanol at 10 mM.
Acrylamide gel electrophoresis and immunoblotting
Proteins were separated by SDS-PAGE using 12% or 15%
polyacrylamide gels as described previously [15]. Immu-
noblotting was performed as described earlier [49].
Pulse-chase experiments and immunoprecipitation
Plasmid-transfected Huh7 cells were starved 24 h post-
transfection for 1 h with DMEM lacking methionine and
cysteine, before cells were labeled with 100 µCi/ml [35S]
methionine and [35S]cysteine (Amersham). After a 30 min
pulse, radioactive medium was replaced by fresh DMEM
and cells were chased for different time intervals as indi-
cated. Cells were lysed in Co-IP buffer (1% NP-40, 0.4%
deoxycholate (DOC), 5 mM EDTA, 100 mM NaCl, 20 mM
Tris-HCl, pH 7.6, 25 mM iodacetamide, 1 mM PMSF).
Nuclei and insoluble debris were removed by centrifuga-
tion at 14 000 rpm and 4°C. Immunoprecipitation of pro-
teins was performed using protein A-Sepharose-coupled
rabbit anti-Z antibodies. Precipitated immunocomplexes
were subsequently analyzed by SDS-PAGE followed by
autoradiography on BioMax films (Kodak).
Flotation experiments
Flotation experiments were carried out as described previ-
ously [15]. Briefly, Z-expressing Huh7 cells were harvested
and disrupted in a hypotonic Tris buffer (20 mM Tris-HCl
[pH 7.4]) by 20 strokes of a Dounce homogenizer on ice.
Nuclei and cell debris were removed from the cell lysate
by low centrifugation at 4°C. OptiPrep (Sigma) was
added to the postnuclear supernatant to a final concentra-
tion of 35% in a total volume of 500 µl, which was placed
at the bottom of a Beckmann-SW60 centrifuge tube. It was
overlaid with 3.5 ml of 30% OptiPrep and then with 200
µl of TNE buffer (25 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 5 mM EDTA). All OptiPrep solutions were prepared
in TNE containing the protease inhibitor mixture Com-
plete (Roche). The gradient was centrifuged to equilib-
rium at 52 000 rpm for 4 h at 4°C. Fractions were
collected from the top, subjected SDS-PAGE and visual-
ized by immunoblotting.
Generation of Z-induced virus-like particles (VLP)
To generate VLPs, Vero cells were transfected with Lassa
virus Z Protein. After 48 h, supernatants cleared from cell
debris were laid on a 20% sucrose cushion and ultracen-
Effect of myristic acid inhibitors on the release of LASV particlesFigure 5
Effect of myristic acid inhibitors on the release of LASV particles. Vero cells were infected with LASV (strain Josiah) 
at a multiplicity of infection of 0.1. At 1 h post-infection, cells were either treated with 3 different myristic acid inhibitors or left 
untreated as indicated. A. 48 hours later cell supernatants were collected and virus yields were determined by TCID50. B. Vir-
ions of cell culture supernatants were passed through a 20% sucrose cushion by ultracentrifugation. Cell lysate and purified vir-
ions were subjected to SDS-PAGE followed by immunoblotting using antiserum specific for indicated proteins.
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trifuged in a SW-60 rotor at 52 000 rpm at 4°C for 2 h. The
pellet was then resuspended in PBS (phosphate-buffered
saline) buffer and analyzed by immunoblotting.
Immunocytochemistry
Vero cells were grown on coverslips and Lipofectamine-
transfected with appropriate plasmid constructs for pro-
tein expression. 24 hours after transfection, cells were
washed and incubated for 5 min with acetone/methanol
(1:1 v/v) for fixation and total permeabilization of mem-
branes. Cells were subsequently washed and incubated for
1 h with 1:100 diluted primary rabbit antibodies followed
by incubation for 45 min with 1:100 diluted anti-rabbit
antibody from goat coupled to FITC (Dianova, Germany).
Protein expression of cells was examined using an
immunofluorescence microscope (Axiophot, Zeiss, Ger-
many).
Treatment of LASV-infected cells with myristoylation 
inhibitors
VeroE6 cells were grown to 80% confluence and infected
with LASV at a MOI of 0.1 PFU/cell. 1 hour post-adsorp-
tion, cells were either treated with different concentra-
tions of DL-2-hydroxymyristic acid (2 OHM), 13-
oxamyristic acid (13 OM) or 4-oxatetradecanoic acid (4
OXA) or left untreated. After 48 hours, cells and superna-
tants were collected. Virus titration was performed by
defining the 50% tissue culture infectious dose (TCID50).
For this, the supernatants were diluted 5-fold and the dilu-
tions were used to infect VeroE6 cells in 96-well plates
(four wells for each dilution). The cultures were scored
periodically for cytopathic effect over a period of 7 days.
The endpoint virus titers for culture supernatants were cal-
culated with the method of Reed and Muench. Viral titers
were expressed as the log10 of the 50% titration endpoint
for infectivity as calculated by the methods of Karber and
Spearman. In addition, the amount of viral proteins
released into the supernatant in the presence or absence of
myristic acid inhibitors was analyzed by immunoblotting.
Therefore, cell lysates and supernatants that were ultracen-
trifuged as described above were collected and lysed in
SDS-PAGE sample buffer.
Abbreviations
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